DaBomb Protein Biotech Corp.

TPEX:6578 Stock Report

Market Cap: NT$1.3b

DaBomb Protein Biotech Management

Management criteria checks 0/4

We currently do not have sufficient information about the CEO.

Key information

Yu Fen Liu

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenureno data
CEO ownership3.8%
Management average tenureno data
Board average tenureno data

Recent management updates

Recent updates

Should You Be Impressed By DaBomb Protein's (GTSM:6578) Returns on Capital?

Feb 17
Should You Be Impressed By DaBomb Protein's (GTSM:6578) Returns on Capital?

DaBomb Protein (GTSM:6578) Has A Somewhat Strained Balance Sheet

Jan 13
DaBomb Protein (GTSM:6578) Has A Somewhat Strained Balance Sheet

Is DaBomb Protein Corp. (GTSM:6578) A Risky Dividend Stock?

Dec 09
Is DaBomb Protein Corp. (GTSM:6578) A Risky Dividend Stock?

CEO

Yu Fen Liu

no data

Tenure

Ms. Yu Fen Liu serves as Chairman and General Manager of DaBomb Protein Biotech Corp. (formerly known as DaBomb Protein Corp.) Ms. Liu served as the Chairman of Board of Directors in DaBomb Protein Company...

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/19 08:51
End of Day Share Price 2024/12/19 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

DaBomb Protein Biotech Corp. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution